Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2017 1
2019 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

3 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Grade 5 Pulmonary Fibrosis, CTCAE"
Page 1
Weight loss in nintedanib-treated patients with idiopathic pulmonary fibrosis.
Tomioka H, Iwabayashi M, Yokota M, Hashimoto R, Amimoto H. Tomioka H, et al. Pulm Pharmacol Ther. 2023 Jun;80:102213. doi: 10.1016/j.pupt.2023.102213. Epub 2023 Mar 29. Pulm Pharmacol Ther. 2023. PMID: 37001796
Nintedanib is approved for the treatment of idiopathic pulmonary fibrosis (IPF). Weight loss is recognized as an adverse event during nintedanib treatment, and is a common complication exploitable as a prognostic indicator of IPF. ...In the model adjusting fo …
Nintedanib is approved for the treatment of idiopathic pulmonary fibrosis (IPF). Weight loss is recognized as an adverse event …
Efficacy of corticosteroid and intravenous cyclophosphamide in acute exacerbation of idiopathic pulmonary fibrosis: A propensity score-matched analysis.
Hozumi H, Hasegawa H, Miyashita K, Yasui H, Suzuki Y, Kono M, Karayama M, Furuhashi K, Hashimoto D, Enomoto N, Fujisawa T, Inui N, Nakamura Y, Yokomura K, Nakamura H, Suda T. Hozumi H, et al. Respirology. 2019 Aug;24(8):792-798. doi: 10.1111/resp.13506. Epub 2019 Feb 25. Respirology. 2019. PMID: 30803100 Free article.
BACKGROUND AND OBJECTIVE: Acute exacerbation (AE) is a leading cause of death in patients with idiopathic pulmonary fibrosis (IPF). Although optimal treatment for AE-IPF remains unclear, high-dose corticosteroids (CS) with/without immunosuppressants, including intra …
BACKGROUND AND OBJECTIVE: Acute exacerbation (AE) is a leading cause of death in patients with idiopathic pulmonary fibrosis ( …
Low body surface area predicts hepatotoxicity of nintedanib in patients with idiopathic pulmonary fibrosis.
Ikeda S, Sekine A, Baba T, Yamanaka Y, Sadoyama S, Yamakawa H, Oda T, Okuda R, Kitamura H, Okudela K, Iwasawa T, Ohashi K, Takemura T, Ogura T. Ikeda S, et al. Sci Rep. 2017 Sep 7;7(1):10811. doi: 10.1038/s41598-017-11321-x. Sci Rep. 2017. PMID: 28883482 Free PMC article.
After the commercialization of nintedanib in Japan, a high incidence of hepatotoxicity resulting in treatment interruption was noted in idiopathic pulmonary fibrosis (IPF) patients treated with nintedanib in our hospital. ...Body surface area (BSA) was significantly …
After the commercialization of nintedanib in Japan, a high incidence of hepatotoxicity resulting in treatment interruption was noted in idio …